News & Analysis on Clinical Trial Services & Contract Research And Development
Novartis has hooked up with the Massachusetts Institute of Technology (MIT) to fund a project aimed at 'revolutionising' pharmaceutical manufacturing and doing away with traditional batch-based production techniques.
Researchers from Novartis have published results using high-throughput screening (HTS) mass spectrometry (MS) techniques for the identification of enzyme inhibitors.
Novartis's potential Type II diabetes blockbuster has been given the green light in the EU after receiving approval.
Although it is over forty years since scientists realised cancer cells don't have the anti-oxidant protective capabilities of normal cells, it seems that only one pharma company has developed a drug to exploit this fact.
Baxter, LifeCyte, arGentis and Pfizer CentreSource have all recently announced new contract manufacturing deals.
DSM has announced the conclusions for the company's complete overhaul as it accelerates the shift to a life sciences and materials sciences company.
Pfizer will appear this week in a Nigerian court to face allegations that it caused the death of Nigerian children over a decade ago when it conducted a clinical trial of its meningitis drug Trovan (trovafloxacin) in the country.